IDEXX Laboratories, Inc.

NasdaqGS:IDXX Stock Report

Market Cap: US$38.9b

IDEXX Laboratories Past Earnings Performance

Past criteria checks 6/6

IDEXX Laboratories has been growing earnings at an average annual rate of 14.9%, while the Medical Equipment industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 10.5% per year. IDEXX Laboratories's return on equity is 55.2%, and it has net margins of 23.3%.

Key information

14.9%

Earnings growth rate

15.8%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate10.5%
Return on equity55.2%
Net Margin23.3%
Next Earnings Update06 Aug 2024

Recent past performance updates

Recent updates

A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital

Jul 02
A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital

Looking For Fast Growth In Healthcare? IDEXX Has You Covered

Jun 28

Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Jun 04
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?

May 21
Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?

IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 03
IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You

Apr 27
What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You

IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet

Apr 11
IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet

IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)

Apr 08

Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Jan 30
Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified

Jan 16

Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Jan 15
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit

Dec 31
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit

IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly

Dec 15
IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly

Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

Oct 26
Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching

Oct 10
Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching

Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?

Sep 07
Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?

Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Jul 04
Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

May 31
These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?

Apr 05
At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?

Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly

Feb 22
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly

Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

Jan 05
Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?

Nov 24
Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?

When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Sep 20
When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories: Outstanding Business, But Valuation Is Key

Aug 15

These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

Aug 15
These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

IDEXX Laboratories Stock Is Very Expensive

Aug 08

IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M

Aug 02

Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?

Jul 26
Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?

Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today

Jul 12
Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today

Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Jun 16
Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories: Great Business, But Still Overvalued

May 25

We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease

May 06
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease

Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?

Apr 23
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?

With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting

Apr 09
With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting

Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Mar 07
Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories And Its Real Value

Feb 02

Revenue & Expenses Breakdown

How IDEXX Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:IDXX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 243,725867925199
31 Dec 233,661845902191
30 Sep 233,588823888183
30 Jun 233,514791877183
31 Mar 233,431699858259
31 Dec 223,367679851255
30 Sep 223,340670848257
30 Jun 223,309664840249
31 Mar 223,274735821164
31 Dec 213,215745796161
30 Sep 213,135757770154
30 Jun 213,047728777152
31 Mar 212,858674739146
31 Dec 202,707582735141
30 Sep 202,591497717138
30 Jun 202,475460674134
31 Mar 202,457437681135
31 Dec 192,407428669133
30 Sep 192,351423657128
30 Jun 192,291407642123
31 Mar 192,252390638120
31 Dec 182,213377632118
30 Sep 182,170330621117
30 Jun 182,117307610115
31 Mar 182,045284596112
31 Dec 171,969263575109
30 Sep 171,906277561106
30 Jun 171,862263547104
31 Mar 171,820245534102
31 Dec 161,775222522101
30 Sep 161,732214516101
30 Jun 161,690202502100
31 Mar 161,63719249399
31 Dec 151,602192482100
30 Sep 151,55417447599
30 Jun 151,53118246799
31 Mar 151,508182457100
31 Dec 141,48618244898
30 Sep 141,48819943596
30 Jun 141,44319342293
31 Mar 141,40519040989
31 Dec 131,37718840188
30 Sep 131,34318838187

Quality Earnings: IDXX has high quality earnings.

Growing Profit Margin: IDXX's current net profit margins (23.3%) are higher than last year (20.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IDXX's earnings have grown by 14.9% per year over the past 5 years.

Accelerating Growth: IDXX's earnings growth over the past year (23.9%) exceeds its 5-year average (14.9% per year).

Earnings vs Industry: IDXX earnings growth over the past year (23.9%) exceeded the Medical Equipment industry 5.5%.


Return on Equity

High ROE: IDXX's Return on Equity (55.2%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.